Group 1 - Jiuxin Traditional Chinese Medicine Group donated medical protective materials worth 120,000 yuan for the "Love Care Class" summer volunteer service project in Hubei [1] - The Hubei Volunteer Association mobilized over 900 volunteer teams from 91 universities, with nearly 20,000 student volunteers participating in the project [3] - The donation from Jiuxin Traditional Chinese Medicine reflects corporate social responsibility and provides strong support for the project's smooth implementation [3] Group 2 - The volunteer representative expressed gratitude, stating that the donated materials are like timely rain in the hot summer, motivating them to provide meaningful service to children [5] - Jiuzhoutong Pharmaceutical Group's Vice President emphasized the company's commitment to public welfare and the promotion of traditional Chinese medicine through such initiatives [6] - Jiuzhoutong's total donations for 2024 exceeded 18 million yuan, with 21 rural revitalization projects, and it was recognized as an "ESG Model Enterprise" [6] - Jiuxin Traditional Chinese Medicine has developed traceable Chinese medicinal material bases in various regions, contributing to a production value of approximately 10 billion yuan and benefiting over 50,000 farmers [6]

北京医院老年医学科副主任李晶教授强调，50岁后随着免疫力自然下降，带状疱疹的发病率会显著升 高，而合并高血压、糖尿病等慢性病的老人风险更高——这些疾病会进一步削弱免疫屏障，让病毒"有 机可乘"。带状疱疹的疼痛可能持续数月甚至数年，严重影响生活质量。因此，预防是守护晚年健康的 关键，而接种疫苗是预防带状疱疹的有效手段。建议符合条件的中老年人主动预防，同时通过均衡饮 食、适度运动和规律作息增强免疫力，保护自身健康。 新京报讯（记者王卡拉）随着中国老龄化进程加速，中老年群体的健康问题日益受到关注。6月23日-29 日为2025年全国老年健康宣传周，呼吁提升老年人健康素养和健康水平。在此背景下，带状疱疹作为中 老年人高发的感染性疾病之一，积极对其进行及早预防和主动管理，已成为助力实现"健康中国2030"目 标及推动"健康老龄化"的关键行动之一。 带状疱疹俗称"蛇缠腰""生蛇"，是由水痘-带状疱疹病毒引发的感染性疾病，而年龄是带状疱疹最重要 的危险因素，50岁以上为带状疱疹易发人群。当前，我国50岁以上人群已超4亿，伴随年龄增长，老年 人免疫功能逐年下降，皮肤防御能力减弱，感染性疾病（如带状疱疹）风险增加，慢性病（糖尿 ...

Core Insights - AstraZeneca is significantly increasing its investment and collaboration efforts in China, including a $2.5 billion investment to establish its sixth global strategic R&D center in Beijing and multiple partnerships with local companies [2][11]. Group 1: Investment and Collaboration - AstraZeneca has invested over $23 billion in partnerships with 14 local Chinese innovative drug companies since 2023, focusing on advanced technologies such as antibody-drug conjugates and cell therapies [5]. - The company plans to launch 20 global innovative drugs by 2030, with a 100% synchronization rate of its R&D pipeline in China [5]. - AstraZeneca's China Medical Industry Fund has invested in 27 Chinese innovative companies, with a total fund size of approximately $550 million [5]. Group 2: Healthcare Innovation and Patient Management - AstraZeneca is committed to improving patient disease management and healthcare experiences through partnerships, aiming to enhance health equity [9]. - The Breast Disease Center has been established in over 150 hospitals, benefiting more than 40,000 breast cancer patients, with a goal to reach over 100,000 patients in three years [9][10]. - The National Standardized Metabolic Disease Management Center has been implemented in over 1,600 hospitals, benefiting over 2.8 million patients, with a threefold increase in comprehensive control rates [9]. Group 3: Strategic Vision and Market Confidence - AstraZeneca's leadership emphasizes confidence in China's reform and opening-up policies, improving business environment, technological advancements, and market potential [11]. - The company has participated in the China International Fair for Trade in Services (CIFTIS) for four consecutive years, viewing it as a vital platform for engaging with government and understanding policy directions [12]. - In 2024, AstraZeneca's total revenue reached $54.1 billion, with China contributing $6.4 billion, accounting for 12% of global revenue [12].

Core Insights - The conference focused on infertility prevention and treatment strategies, emphasizing the innovative application of traditional Chinese medicine (TCM) in reproductive health [1][3][5] Group 1: Conference Overview - The second academic annual meeting and expert tour on infertility and reproductive health was successfully held in Chengdu, organized by the China Medical Education Association and supported by Good Doctor Group and Shenyang Qinggong Pharmaceutical Group [1] - The event gathered renowned experts, scholars, and clinicians in the field of TCM and reproductive health to share authoritative reports, specialized discussions, and practical case studies [1] Group 2: Keynote Highlights - Huang Zhengming, Honorary President of the China Medical Education Association, emphasized the importance of grassroots TCM revitalization and the integration of TCM and Western medicine to address reproductive health challenges [3] - The meeting outlined three strategic actions: strengthening grassroots talent through new expert committee members, honoring frontline doctors as "guardians of health," and promoting specialized courses on infertility to enhance technical capabilities [3] Group 3: Expert Contributions - Huang Zhengming analyzed the dynamic changes in China's fertility rate, discussing the direct impact of contemporary social phenomena on reproductive willingness [5] - Wang Zheng, Vice Chairman of the Health and Medicine Committee of the Chinese People's Political Consultative Conference, highlighted TCM's unique advantages in regulating menstruation and improving endometrial receptivity, advocating for a collaborative approach between TCM and Western medicine [5] Group 4: Initiatives and Future Plans - The Good Doctor Group announced the launch of the "Infertility Reproductive Health Expert Tour" in April 2024, which has already assisted over 5,000 families in overcoming fertility challenges [5] - Aiming for long-term development, the Good Doctor Group plans to establish a "China Reproductive Health Industry Base" centered around Shenyang Qinggong Pharmaceutical, integrating TCM heritage with cutting-edge technology to enhance training and resource allocation for grassroots doctors [5] Group 5: Consensus and Goals - The conference reached a consensus on enhancing reproductive health service levels, contributing to national population strategies, and supporting the "Healthy China 2030" initiative [7]

Core Insights - The company, LeGua, is positioned as an innovative leader in the health sleep posture sector, capitalizing on the growing demand for quality sleep in China under the "Healthy China 2030" strategy [1] Group 1: Market Performance - LeGua's sleep pillows have achieved significant sales across major e-commerce platforms, holding multiple top positions in sales rankings [2] - On Douyin, LeGua occupies two spots in the top five of the "Bedding Pillow Bestsellers" list, with LeLeTu's sleep pillow leading due to high repurchase rates [2] - On Tmall, LeGua has risen to the second place in the overall pillow category, showcasing strong product capability and market recognition [2] - On JD.com, LeGua holds five positions in the top 15 of the "Cotton Pillow Bestsellers," with the "Cute Dinosaur Sleep Pillow" ranking first [2] - LeGua's "Cool Skin Series Sleep Pillow" has gained popularity in Sam's Club, indicating strong performance in high-end retail channels [2] Group 2: Product Innovation - LeGua's core competitiveness lies in its focus on "ergonomics + sleep science," with product designs that promote healthy sleeping postures [3] - The company has accumulated 59 global patents across six technical fields, including ergonomic design and elastic filling, creating a comprehensive product system to meet diverse user needs [3] Group 3: Brand Reputation - LeGua has received widespread positive feedback across various channels, including online platforms and offline recognition in Sam's Club [4] - The brand is actively recommended by users on social media platforms like Xiaohongshu and Douyin, reinforcing its market position and brand influence in the sleep health sector [4] Group 4: Customer-Centric Philosophy - LeGua's "customer-centric" philosophy is rooted in the founder's personal experience, emphasizing the need to balance emotional and functional demands for healthy sleep [5] - The company is committed to promoting the concept of "actively caring for sleep health" in daily life, aiming to make healthy sleep postures a common practice among the public [5]

为助力健康中国行动，普及慢病防控知识，提高人民群众健康素养，6月21日，由中国疾控中心慢病中心与人民健康共同发起的"2025慢病防控优质科普 传播推广行动"启动。此次行动汇聚政府、医疗与社会各界力量，共同探索慢病防控科普的创新路径，助力健康中国战略深入实施。 "慢性病是我们今后将要长期面对的公共卫生挑战，仍需多方合力，久久为功。"中国疾病预防控制中心副主任严俊强调了预防优先的策略，她说："在 推进慢病防控过程中，不仅需要加强健康教育人才队伍建设，还需要通过激励政策和制度保障，让更多医务卫生人员愿意投身健康教育和健康科普；不仅需 要公众提升'做自己健康第一责任人'意识，重视健康、维护健康、享受健康，也需要社会各界积极参与慢性病防控工作，将慢性病防控融入健康中国建设大 局之中，构建更加完善、更加高效、更加精准的慢性病防控体系，推进关口前移。" 中国疾控中心慢病中心主任吴静对"2024年慢病防控优质科普传播推广行动"的成果进行了全面回顾。"过去一年中，行动通过多渠道传播、多形式创 作，推出了一系列贴近民生、形式新颖、通俗易懂的科普作品，有效提升了公众对慢病防治的认知。项目启动以来，陆续收到科普内容超过2.3万条，作 ...

为推动杜仲产业高质量发展，助力健康中国建设，2025年6月20日至21日，中国中药协会以"杜仲助力健 康中国-杜仲与痿病防治"为主题，在北京隆重举行了第六届杜仲大会。 吴宪副会长在致辞中指出，杜仲产业在坚守中传承创新，走出了一条以高质量发展为目标的康庄大道。 杜仲产业已在中医药领域崭露头角，在食品、保健品、日化领域焕发新生，成为大健康产业的关键核心 资源。杜仲标准化种植规模快速发展为产业繁荣筑牢根基。杜仲的良种选育实现突破，杜仲加工技术推 陈出新，杜仲胶的研发开辟了材料科学新领域，"药食同源"如星火燎原，让杜仲在大健康产业中枝繁叶 茂。 国家药品监督管理局原副局长赵军宁、中国工程院院士田金洲,中国工程院院士肖伟，中国工程院院士 朱立国出席大会并作学术报告。来自国家部委、科研院校、协会学会，以及全国杜仲主产区主管部门、 杜仲产学研用单位和媒体机构代表300余人参会。 18746 . . . 中国中国特金重大国际开大 . . .. .. .. ..... 49 0 中医药高质量医疗服务的需求、瓶颈及策略 田金洲 Standards of exce te lead to high cal can 北京中医药大学东直 ...

会议强调， 于文明涉嫌严重职务违法警醒我们，党风廉政建设和反腐败斗争形势仍然严峻 复杂，必须保持永远在路上的坚韧和执着，坚决打好反腐败斗争攻坚战持久战总体战。 要 扛牢管党治党政治责任，严格落实党组主体责任、主要责任人第一责任人责任，领导班子其 他成员"一岗双责"，坚持以身作则，严于律己、严管所辖，强化对各级"一把手"和领导班子 的监督，以更严的标准、更实的要求，进一步推动正风肃纪反腐走深走实。 会议强调，要坚持不懈用习近平新时代中国特色社会主义思想凝心铸魂，学深悟透习近平总 书记关于党的建设的重要思想、关于党的自我革命的重要思想，坚决同一切违纪违法行为作 斗争。从严从实推动深入贯彻中央八项规定精神学习教育，抓严抓实学查改各项工作，自觉 把中央八项规定作为长期有效的铁规矩、硬杠杠。要树牢正确权力观、政绩观、事业观，把 为民造福作为最大政绩，做到公正用权、依法用权、为民用权、廉洁用权。要时刻自重自省 自警、慎独慎初慎微，从严教育、管理、监督亲属和身边工作人员，进一步强化纪律意识和 规矩意识，真正做到自身正、自身硬、自身廉。 会议要求，全局各级党组织和广大党员干部要深入学习贯彻习近平总书记关于健康中国建设 和中医 ...

你的体重，正在悄然重新书写健康人生的剧本！这是一场关乎生命质量的较量，你就是主角！你是否意识到，每一次对体重的放纵，都可能在 为高血压、糖尿病、心脑血管疾病甚至癌症打开大门？国家卫健委权威提醒：慢性病已成为国民健康的"头号威胁"，而体重失控正是引发这一 危机的关键因素！ 以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 随着生活水平提升，我们的餐桌越来越丰富，但运动却被逐渐忽视。高热量饮食带来的不仅是体重的上升，更是健康的隐患。脂肪肝、代谢紊 乱、关节损伤……这些疾病正随着体重的增加悄然逼近。但别担心，国家已经吹响了"健康集结号"——"体重管理年"三年行动正式拉开帷幕！ 这不仅仅是个人形象的管理，更是全民健康的国家战略。从现在开始，你就是自己健康的第一守护人！ 无需极端节食，也不必盲目运动！只需从每餐少吃一口油盐、每天多走一千步做起，科学调整饮食结构，规律坚持适量锻炼，让健康成为生活 的主旋律。用轻盈的步伐取代沉重的喘息，用健康的体态迎接更好的自己。这场全民减重行动，需要你的积极参与！转发提醒身边人： ...

Group 1 - The establishment of the Shandong branch of Zhongke Boai (Beijing) Health Technology Co., Ltd. in Jinan marks an important step in the company's national strategic layout and a commitment to the health sector in Qilu [2] - The company aims to provide high-quality and convenient health services by leveraging Shandong's cultural heritage and regional advantages, contributing to the "Healthy China" strategy [2] - The chairman, Cui Xiansheng, emphasizes the importance of mental health and plans to use professional knowledge to make significant contributions to society [2] Group 2 - The company has appointed experts from the Jinan Mental Health Association and Shandong Mental Health Center as advisory consultants, enhancing its professional capabilities [3] - Future plans include developing personalized health solutions based on local needs, increasing research investment, and integrating AI and big data with health services [3] - The company aims to build a health ecosystem in collaboration with local institutions, benefiting a wider community and supporting mental health initiatives in Qilu [3]